KR20220048045A - 질환을 치료하기 위한 5ht 작용제 - Google Patents

질환을 치료하기 위한 5ht 작용제 Download PDF

Info

Publication number
KR20220048045A
KR20220048045A KR1020227011498A KR20227011498A KR20220048045A KR 20220048045 A KR20220048045 A KR 20220048045A KR 1020227011498 A KR1020227011498 A KR 1020227011498A KR 20227011498 A KR20227011498 A KR 20227011498A KR 20220048045 A KR20220048045 A KR 20220048045A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
receptor agonist
clemizole
pharmaceutically acceptable
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020227011498A
Other languages
English (en)
Korean (ko)
Inventor
스코트 씨 바라반
Original Assignee
더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 filed Critical 더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Priority to KR1020237037303A priority Critical patent/KR20230152844A/ko
Publication of KR20220048045A publication Critical patent/KR20220048045A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227011498A 2015-02-25 2016-02-24 질환을 치료하기 위한 5ht 작용제 Ceased KR20220048045A (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020237037303A KR20230152844A (ko) 2015-02-25 2016-02-24 질환을 치료하기 위한 5ht 작용제

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562120726P 2015-02-25 2015-02-25
US62/120,726 2015-02-25
PCT/US2016/019368 WO2016138138A1 (en) 2015-02-25 2016-02-24 5ht agonists for treating disorders
KR1020177026528A KR102385665B1 (ko) 2015-02-25 2016-02-24 질환을 치료하기 위한 5ht 작용제

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177026528A Division KR102385665B1 (ko) 2015-02-25 2016-02-24 질환을 치료하기 위한 5ht 작용제

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020237037303A Division KR20230152844A (ko) 2015-02-25 2016-02-24 질환을 치료하기 위한 5ht 작용제

Publications (1)

Publication Number Publication Date
KR20220048045A true KR20220048045A (ko) 2022-04-19

Family

ID=56789223

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020227011498A Ceased KR20220048045A (ko) 2015-02-25 2016-02-24 질환을 치료하기 위한 5ht 작용제
KR1020177026528A Active KR102385665B1 (ko) 2015-02-25 2016-02-24 질환을 치료하기 위한 5ht 작용제
KR1020237037303A Pending KR20230152844A (ko) 2015-02-25 2016-02-24 질환을 치료하기 위한 5ht 작용제

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020177026528A Active KR102385665B1 (ko) 2015-02-25 2016-02-24 질환을 치료하기 위한 5ht 작용제
KR1020237037303A Pending KR20230152844A (ko) 2015-02-25 2016-02-24 질환을 치료하기 위한 5ht 작용제

Country Status (21)

Country Link
US (5) US10874643B2 (https=)
EP (4) EP4043016B1 (https=)
JP (5) JP6884703B2 (https=)
KR (3) KR20220048045A (https=)
CN (2) CN113546174A (https=)
AU (3) AU2016222804C1 (https=)
BR (1) BR112017018297B1 (https=)
CA (2) CA2977135C (https=)
CY (1) CY1125360T1 (https=)
DK (1) DK3261640T3 (https=)
EA (2) EA201992474A3 (https=)
ES (2) ES2920886T3 (https=)
HR (1) HRP20220822T1 (https=)
HU (1) HUE059559T2 (https=)
LT (1) LT3261640T (https=)
PL (1) PL3261640T3 (https=)
PT (1) PT3261640T (https=)
RS (1) RS63426B1 (https=)
SI (1) SI3261640T1 (https=)
SM (1) SMT202200276T1 (https=)
WO (1) WO2016138138A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119564685A (zh) * 2024-12-16 2025-03-07 中国人民解放军军事科学院军事医学研究院 Yl-0919在癫痫或癫痫导致的脑损伤治疗中的应用

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
CN113546174A (zh) 2015-02-25 2021-10-26 加利福尼亚大学董事会 用于治疗病症的5ht激动剂
GB201620095D0 (en) * 2016-11-28 2017-01-11 Terali Innov Sas And Univ De Strasbourg And Inserm (Inst Nat De La Sante Et De La Rech Medicale) And Novel use
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
PT4293009T (pt) 2015-12-22 2025-09-08 Zogenix International Ltd Composições de fenfluramina e métodos de preparação das mesmas
AU2017315273B2 (en) 2016-08-24 2021-04-29 Zogenix International Limited Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same
WO2018115010A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine and polysiloxane or polyisobutylene
ES2769286T3 (es) 2016-12-20 2020-06-25 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina
ES2881783T3 (es) 2017-06-26 2021-11-30 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico que contiene asenapina y polímero de acrílico y silicona
US10682317B2 (en) * 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EP3806835A1 (en) 2018-06-14 2021-04-21 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
CA3101420A1 (en) 2018-06-20 2019-12-26 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
US12268683B2 (en) 2018-07-18 2025-04-08 The Regents Of The University Of California Compounds and methods for synergistic activation of M channels
WO2020023923A1 (en) * 2018-07-27 2020-01-30 Xenon Pharmaceuticals Inc. Method for treating epilepsy
AU2019384963B2 (en) 2018-11-19 2022-05-26 Zogenix International Limited Methods of treating Rett syndrome using fenfluramine
EP3976187A4 (en) * 2019-05-29 2023-08-02 The Regents of the University of California METHODS AND COMPOSITIONS FOR THE TREATMENT OF EPILEPSY
EP3791873A1 (en) 2019-09-16 2021-03-17 Universite De Bordeaux Methods of treatment and/or prevention of disorders and symptoms related to bkca and/or sk channelophathies
KR20220087507A (ko) * 2019-10-23 2022-06-24 뉴로사이클 테라퓨틱스, 인크. Gabaa 수용체 조절제를 사용한 간질 병태의 치료
FI4048249T3 (fi) * 2019-10-23 2025-12-05 Maplight Therapeutics Inc Menetelmiä autismikirjon häiriön oireiden hoitamiseksi
KR20210054684A (ko) 2019-11-06 2021-05-14 동국대학교 경주캠퍼스 산학협력단 라미나린을 유효성분으로 함유하는 허혈성 뇌혈관 질환 예방용 조성물
JP7780431B2 (ja) * 2019-12-06 2025-12-04 マリナス ファーマシューティカルズ， インコーポレイテッド 結節性硬化症の治療での使用のためのガナキソロン
KR102476771B1 (ko) * 2020-05-08 2022-12-13 광운대학교 산학협력단 뇌질환 검증용 eeg 바이오 마커 분석 알고리즘을 통하여 소아 뇌전증 환자 미주신경자극술 효과를 예측하는 방법
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
BR112023019407A2 (pt) * 2021-03-25 2023-11-28 Maplight Therapeutics Inc Composições farmacêuticas compreendendo zolmitriptano
EP4346804A4 (en) * 2021-06-01 2025-05-07 Arena Pharmaceuticals, Inc. TREATMENT PROCEDURES
CN117580579A (zh) * 2021-06-10 2024-02-20 纽瑞莱斯有限公司 用于治疗儿科患者的癫痫发作病症的方法和组合物
CN118043034A (zh) * 2021-07-30 2024-05-14 艾匹真尼克斯治疗公司 克立咪唑制剂
WO2023107965A1 (en) * 2021-12-06 2023-06-15 Terran Biosciences, Inc. Salt and solid forms of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (dom), 2,5-dimethoxy-4-iodoamphetamine (doi), 2,5-dimethoxy-4-bromoamphetamine (dob), and 2,5-dimethoxy-4-chloroamphetamine (doc)
US11974992B2 (en) 2022-01-26 2024-05-07 Neurolixis Use of serotonin 5-HT1A receptor agonists to treat diseases associated with sudden unexpected death in epilepsy
WO2023144166A1 (en) 2022-01-26 2023-08-03 Neurolixis Use of serotonin 5-ht1a receptor agonists to treat diseases associated with sudden unexpected death in epilepsy
WO2023212244A1 (en) * 2022-04-27 2023-11-02 Tessellate Therapeutics, Inc. Methods of treating 5ht2a receptor-mediated conditions
CA3247344A1 (en) 2022-06-09 2023-12-14 Diamond Therapeutics Inc. AMORPHIC PSILOCYBIN (A-POLYMORPHIC)
WO2024118280A1 (en) * 2022-11-30 2024-06-06 Mind Medicine, Inc. 4-alkenyl and 4-alkynyl phenethylamine derivatives and related compounds with modified dom-like action

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2436883C2 (de) 1974-07-29 1985-08-22 Schering AG, 1000 Berlin und 4709 Bergkamen Benzimidazol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
ATE141502T1 (de) 1991-01-15 1996-09-15 Alcon Lab Inc Verwendung von karrageenan in topischen ophthalmologischen zusammensetzungen
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6323237B1 (en) * 1997-03-17 2001-11-27 Btg International Limited Therapeutic compositions
GB9927844D0 (en) * 1999-11-26 2000-01-26 Glaxo Group Ltd Chemical compounds
US7326536B2 (en) 2001-05-03 2008-02-05 Eli Lilly And Company Agents for treatment of HCV and methods of use
US6559293B1 (en) 2002-02-15 2003-05-06 Transform Pharmaceuticals, Inc. Topiramate sodium trihydrate
US7582428B2 (en) 2003-08-22 2009-09-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for identifying anti-HCV agents
US20050215589A1 (en) 2003-09-03 2005-09-29 Roger Crossley Inhibitors of 5-HT2A receptor
EP1787679A1 (en) * 2005-07-29 2007-05-23 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of diabetes-associated pain
US7635710B2 (en) 2006-02-15 2009-12-22 Neurim Pharmaceuticals (1991) Ltd. Pyrone-indole derivatives and process for their preparation
EP2068872A1 (en) * 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US8642351B2 (en) 2006-09-20 2014-02-04 Waters Technologies Corporation Apparatus and methods of fluid chromatography
US8402815B2 (en) 2007-04-06 2013-03-26 Koninklijke Philips Electronics N.V. Air pollution sensor system
TW200848063A (en) * 2007-04-23 2008-12-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
CA2687715A1 (en) 2007-05-09 2008-11-20 Traffick Therapeutics Inc. Screening assay to identify correctors of protein trafficking defects
EP2203168B1 (en) 2007-09-18 2014-07-16 Stanford University Compositions for treating a flaviviridae family viral infection
KR100925176B1 (ko) 2007-09-21 2009-11-05 한국전자통신연구원 지리 정보를 이용한 네트워크 상태 표시장치 및 방법
BRPI0908098A2 (pt) 2008-02-19 2015-08-18 Adolor Corp Beloxepina, composição, métodos para tratar dor em um mamífero, para inibir a recaptação de ne, para antagonizar um receptor de 5ht2 e para tratar um distúrbio em um paciente que é responsivo ao tratamento com um composto nri e com um composto antagonista de 5ht2
CN102066319A (zh) 2008-04-16 2011-05-18 艾尼纳制药公司 用于合成(r)-1-{2-[4’-(3-甲氧基丙-1-磺酰基)-联苯-4-基]-乙基}-2-甲基-吡咯烷的方法
DK2307035T3 (da) 2008-05-16 2014-01-20 Nono Inc Anvendelse af en PSD-95 inhibitor ved behandlingen af epilepsi
WO2010039195A2 (en) 2008-09-23 2010-04-08 The Board Of Trustees Of The Leland Stanford Junior University Screening for inhibitors of hcv amphipathic helix (ah) function
WO2010107739A2 (en) 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a flaviviridae family viral infection
EP2408448A4 (en) 2009-03-18 2012-09-19 Univ Leland Stanford Junior METHODS AND COMPOSITIONS FOR TREATING INFECTION WITH A FLAVIVIRIDAE FAMILY VIRUS
US8772479B2 (en) 2009-05-13 2014-07-08 Nektar Therapeutics Oligomer-containing substituted aromatic triazine compounds
EP2491033A4 (en) 2009-10-20 2013-03-13 Eiger Biopharmaceuticals Inc AZAINDAZOLES FOR THE TREATMENT OF FLAVIVIRIDAE VIRUS INFECTION
WO2014123909A1 (en) 2013-02-05 2014-08-14 University Of Washington Through Its Center For Commercialization Positive allosteric modulators of the gaba-a receptor in the treatment of autism
US9549909B2 (en) * 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
DK3035926T3 (da) * 2013-08-19 2020-08-31 Univ California Forbindelser og fremgangsmåder til behandling af en epilepsilidelse
WO2015066344A1 (en) * 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2015096119A1 (zh) * 2013-12-27 2015-07-02 杭州普晒医药科技有限公司 氯卡色林盐及其晶体、其制备方法和用途
CN113546174A (zh) 2015-02-25 2021-10-26 加利福尼亚大学董事会 用于治疗病症的5ht激动剂
GB2539472A (en) * 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN119564685A (zh) * 2024-12-16 2025-03-07 中国人民解放军军事科学院军事医学研究院 Yl-0919在癫痫或癫痫导致的脑损伤治疗中的应用

Also Published As

Publication number Publication date
AU2021204261A1 (en) 2021-07-29
CA3204599A1 (en) 2016-09-01
EP3261640B1 (en) 2022-04-06
EP3261640A1 (en) 2018-01-03
ES2920886T3 (es) 2022-08-11
RS63426B1 (sr) 2022-08-31
US20210154171A1 (en) 2021-05-27
US11648237B2 (en) 2023-05-16
LT3261640T (lt) 2022-07-11
JP2020143087A (ja) 2020-09-10
SI3261640T1 (sl) 2022-10-28
US20260083706A1 (en) 2026-03-26
EA201992474A2 (ru) 2020-02-28
HRP20220822T1 (hr) 2022-10-28
BR112017018297A2 (pt) 2018-04-17
JP2022116307A (ja) 2022-08-09
CA2977135C (en) 2023-08-22
AU2016222804C1 (en) 2021-10-14
HUE059559T2 (hu) 2022-12-28
AU2022203274A1 (en) 2022-06-16
EP3632434A1 (en) 2020-04-08
JP6884703B2 (ja) 2021-06-09
JP2021185148A (ja) 2021-12-09
WO2016138138A1 (en) 2016-09-01
CA2977135A1 (en) 2016-09-01
EA201791882A1 (ru) 2018-02-28
ES3060954T3 (en) 2026-03-30
EP4696377A2 (en) 2026-02-18
CN107530326B (zh) 2021-09-21
AU2022203274B2 (en) 2024-08-15
JP2018506555A (ja) 2018-03-08
PT3261640T (pt) 2022-07-06
KR102385665B1 (ko) 2022-04-14
CY1125360T1 (el) 2025-05-09
EP4043016A1 (en) 2022-08-17
DK3261640T3 (da) 2022-07-11
AU2016222804A1 (en) 2017-08-31
JP7846506B2 (ja) 2026-04-15
EP3261640A4 (en) 2018-12-19
CN107530326A (zh) 2018-01-02
PL3261640T3 (pl) 2022-10-31
CN113546174A (zh) 2021-10-26
US12447144B2 (en) 2025-10-21
BR112017018297B1 (pt) 2023-12-05
AU2021204261B2 (en) 2023-08-10
EP4696377A3 (en) 2026-04-29
SMT202200276T1 (it) 2022-09-14
JP2024009839A (ja) 2024-01-23
US20230346750A1 (en) 2023-11-02
EA201992474A3 (ru) 2020-05-31
US20180028499A1 (en) 2018-02-01
KR20230152844A (ko) 2023-11-03
KR20170118870A (ko) 2017-10-25
EP4043016B1 (en) 2025-10-29
US10874643B2 (en) 2020-12-29
AU2016222804B2 (en) 2021-07-15
US20200147048A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
KR102385665B1 (ko) 질환을 치료하기 위한 5ht 작용제
US12419866B2 (en) Compounds and methods for treating an epileptic disorder
HK40062533A (zh) 用於治疗病症的5ht激动剂
HK40079848A (en) The 5ht agonist clemizole for use in treating epilepsy disorders
EA046651B1 (ru) Агонисты 5ht для лечения нарушений
EA040818B1 (ru) Способ лечения эпилептического расстройства с помощью агониста рецептора 5ht

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220406

Application number text: 1020177026528

Filing date: 20170920

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220504

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220712

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230530

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20220712

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
J201 Request for trial against refusal decision
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20231030

Application number text: 1020177026528

Filing date: 20170920

PJ0201 Trial against decision of rejection

Patent event date: 20231030

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20230530

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Appeal identifier: 2023101002324

Request date: 20231030

J301 Trial decision

Free format text: TRIAL NUMBER: 2023101002324; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20231030

Effective date: 20250425

PJ1301 Trial decision

Patent event code: PJ13011S01D

Patent event date: 20250425

Comment text: Trial Decision on Objection to Decision on Refusal

Appeal kind category: Appeal against decision to decline refusal

Request date: 20231030

Decision date: 20250425

Appeal identifier: 2023101002324